{"id":"W2597432644","doi":"10.1016/j.ejca.2017.01.024","title":"Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Prostate cancer; Abiraterone acetate; Internal medicine; Cancer; Cmax; Oncology; Pharmacology; Pharmacokinetics; Urology; Androgen deprivation therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001208782,0.001910827,0.003242596,0.0008327522,0.0006190694,0.00179823,0.00141403,0.001579356,0.006665341],"category_scores_gemma":[0.001378095,0.00116484,0.002334953,0.0008321468,0.001329367,0.001328382,0.0004113617,0.004934811,0.00179721],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00123641,"about_ca_system_score_gemma":0.002214697,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002937596,"about_ca_topic_score_gemma":0.006728299,"domain_scores_codex":[0.999448,0.0002464758,0.00002702082,0.0001028718,0.00005214692,0.0001234339],"domain_scores_gemma":[0.9990892,0.0001505795,0.0001555338,0.00008854191,0.00004536303,0.0004706842],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8716292,0.03973697,0.001755167,0.0007830505,0.002026294,0.0001286492,0.0002108024,0.002926192,0.01833124,0.0002781687,0.002978286,0.05921601],"study_design_scores_gemma":[0.8014916,0.1889558,0.003788536,0.00003438874,0.0006903791,0.0001559094,0.00007202606,0.0009256151,0.001410591,0.0002973821,0.002135062,0.00004267985],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9839478,0.00526332,0.0009596538,0.0009812965,0.0004469828,0.002336886,0.001893268,0.0002835343,0.003887265],"genre_scores_gemma":[0.9850096,0.003739555,0.001810702,0.001048157,0.0002688223,0.001548969,0.00220823,0.00007801301,0.004288018],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006665341,"threshold_uncertainty_score":0.0222978,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07111369384903171,"score_gpt":0.3939819211044353,"score_spread":0.3228682272554036,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}